Related references
Note: Only part of the references are listed.The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets
Si Sun et al.
ONCOTARGET (2017)
BRCA mutations in the manifestation and treatment of ovarian cancer
Zimin Pan et al.
ONCOTARGET (2017)
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Spyridon P. Basourakos et al.
CURRENT MEDICINAL CHEMISTRY (2017)
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
G. E. Konecny et al.
BRITISH JOURNAL OF CANCER (2016)
A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis
Yali Han et al.
DISEASE MARKERS (2016)
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Aniello Cerrato et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve Clinical Care and Disease Prevention
Katherine Karakasis et al.
FRONTIERS IN ONCOLOGY (2016)
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
Xi-Chun Hu et al.
LANCET ONCOLOGY (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Recurrent mutations of BRCA1 and BRCA2 in Poland: an update
M. Szwiec et al.
CLINICAL GENETICS (2015)
Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries
Janusz Menkiszak et al.
Ginekologia Polska (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
Barbara Lupo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer
Fatemeh Karami et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go
Angela Vasaturo et al.
FRONTIERS IN IMMUNOLOGY (2013)
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management
Simone Heidemann et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
STRUCTURE-FUNCTION OF THE TUMOR SUPPRESSOR BRCA1
Serena L. Clark et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2012)
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy et al.
NATURE REVIEWS CANCER (2012)
Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population
O. Lavie et al.
ANNALS OF ONCOLOGY (2011)
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
Rinske Drost et al.
CANCER CELL (2011)
Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
Ali I. Shamseddine et al.
CHEMOTHERAPY (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein
Apichart Atipairin et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2011)
BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells
Joshua D. O'Donnell et al.
GYNECOLOGIC ONCOLOGY (2010)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
J. Thomas DeLigio et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo
Pierfrancesco Tassone et al.
CANCER BIOLOGY & THERAPY (2009)
BRCA1-Associated Protein 1 Interferes with BRCA1/BARD1 RING Heterodimer Activity
Hiroyuki Nishikawa et al.
CANCER RESEARCH (2009)
Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer
K. Rhiem et al.
CLINICAL ONCOLOGY (2009)
Structural basis for recruitment of BRCA2 by PALB2
Antony W. Oliver et al.
EMBO REPORTS (2009)
PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
Fan Zhang et al.
MOLECULAR CANCER RESEARCH (2009)
Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer
Fleur Huang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
Olafur Andri Stefansson et al.
BREAST CANCER RESEARCH (2009)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
Platinum resistance: The role of DNA repair pathways
Lainie P. Martin et al.
CLINICAL CANCER RESEARCH (2008)
BRCAness Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations
David S. P. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
Bernard Friedenson
BMC CANCER (2007)
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Interactions between human BRCA2 protein and the meiosis-specific recombinase DMC1
Tina Thorslund et al.
EMBO JOURNAL (2007)
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study
Antonino Musolino et al.
BREAST (2007)
Meta-analysis of BRCA1 and BRCA2 penetrance
Sining Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions
Steven R. Bartz et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects
B. Evers et al.
ONCOGENE (2006)
DSS1 is required for the stability of BRCA2
J Li et al.
ONCOGENE (2006)
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions
Ronit I. Yarden et al.
MOLECULAR CANCER THERAPEUTICS (2006)
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis
William D. Foulkes
FAMILIAL CANCER (2006)
High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer
SJ Kim et al.
CLINICAL CANCER RESEARCH (2005)
Flexible nets - The roles of intrinsic disorder in protein interaction networks
AK Dunker et al.
FEBS JOURNAL (2005)
Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex
AK Varma et al.
BIOCHEMISTRY (2005)
BRCA2 regulates homologous recombination in response to DNA damage: Implications for genome stability and carcinogenesis
C Abaji et al.
CANCER RESEARCH (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Characterization of segments from the central region of BRCA1: An intrinsically disordered scaffold for multiple protein-protein and protein-DNA interactions?
WY Mark et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells
K Gudmundsdottir et al.
EMBO REPORTS (2004)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair
JR Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
L Hughes-Davies et al.
CELL (2003)
Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation
SN Powell et al.
ONCOGENE (2003)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
A Antoniou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Improved survival in women with BRCA-associated ovarian carcinoma
I Cass et al.
CANCER (2003)
BRCA I expression modulates chemosensitivity of BRCA I-defective HCC1937 human breast cancer cells
P Tassone et al.
BRITISH JOURNAL OF CANCER (2003)
Insights into DNA recombination from the structure of a RAD51-BRCA2 complex
L Pellegrini et al.
NATURE (2002)
BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure
HJ Yang et al.
SCIENCE (2002)
BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage
RI Yarden et al.
NATURE GENETICS (2002)
Structure of a BRCA1-BARD1 heterodimeric RING-RING complex
PS Brzovic et al.
NATURE STRUCTURAL BIOLOGY (2001)
Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1
RS Williams et al.
NATURE STRUCTURAL BIOLOGY (2001)
Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress
RS Tibbetts et al.
GENES & DEVELOPMENT (2000)
BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines
M Thangaraju et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Partners and pathways - repairing a double-strand break
JE Haber
TRENDS IN GENETICS (2000)
Share Paper
